World News

The expanded facility will allow Siemens Healthineers to increase production of its PET detector technology and respond to growing demand from healthcare providers.

It will house about 325 employees, including 260 laboratory scientists, and provide adaptable laboratories, collaborative workspaces and shared technology platforms.

Solstice Oncology plans to begin enrolment in a Phase II clinical trial of porustobart in combination with pembrolizumab in the fourth quarter of 2026.

Encoded plans to use the proceeds primarily to fund a pivotal trial of ETX101 in infants and young children with SCN1A positive Dravet syndrome.

The rollout follows the drug’s approval in China in June 2026 and marks the start of its wider clinical use for people requiring urgent post-exposure protection against rabies.

The acquisition brings MLM’s laboratory infrastructure and scientific expertise into Labcorp’s global network, creating a broader platform to support clinical trials across multiple regions.

Kerry will work with governments, development partners, multilateral institutions, civil society and the private sector to advocate for stronger health systems and more sustainable health financing.

Nyxoah plans to enrol and implant up to 229 patients at as many as 25 sites, with participants receiving follow-up for up to five years after implantation.

Although Aedes aegypti mosquitoes have been detected in the UK several times in recent years, the latest findings provide the first evidence that the species is actively breeding in Britain.

Novartis India’s board approved the transaction before the company signed an asset purchase agreement and trademark assignment deeds with Pfizer and Pfizer Products.